Abstract | BACKGROUND: the mainstay of treatment of polymyalgia rheumatica (PMR) is oral glucocorticoids, but randomized controlled trials of treatment are lacking. As a result, there is no evidence from controlled studies on the efficacy of different initial doses or glucocorticoid tapering. The aim of this study is to test if 12.5 mg prednisone/day is an adequate starting dose in PMR and to evaluate clinical predictors of drug response. METHODS: 60 consecutive PMR patients were treated with a starting dose of 12,5 mg/day prednisone. Clinical, laboratory, and, in a subset of 25 patients, ultrasonographic features were recorded as possible predictors of response to prednisone. Remission was defined as disappearance of at least 75% of the signs and symptoms of PMR and normalization of ESR and CRP within the first month, a scenario allowing steroid tapering. RESULTS: 47/60 (78.3%) patients responded to 12.5 mg of prednisone after a mean interval of 6.6±5.2 days. In univariate analysis, body weight and gender discriminated the two groups. In multivariate analysis, the only factor predicting a good response was low weight (p=0.004); the higher response rate observed in women was explained by their lower weight. The mean prednisone dose per kg in the responders was 0.19±0.03 mg in comparison with 0.16±0.03 mg for non responders (p=0.007). CONCLUSIONS: 12.5 mg prednisone is a sufficient starting dose in ¾ of PMR patients. The main factor driving response to prednisone in PMR was weight, a finding that could help in the clinical care of PMR patients and in designing prospective studies of treatment. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01169597.
|
Authors | Marco A Cimmino, Massimiliano Parodi, Carlomaurizio Montecucco, Roberto Caporali |
Journal | BMC musculoskeletal disorders
(BMC Musculoskelet Disord)
Vol. 12
Issue 1
Pg. 94
(May 14 2011)
ISSN: 1471-2474 [Electronic] England |
PMID | 21569559
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Glucocorticoids
- C-Reactive Protein
- Prednisone
|
Topics |
- Administration, Oral
- Aged
- Analysis of Variance
- Biomarkers
(blood)
- Blood Sedimentation
- Body Weight
- C-Reactive Protein
(metabolism)
- Drug Dosage Calculations
- Female
- Glucocorticoids
(administration & dosage)
- Humans
- Male
- Middle Aged
- Polymyalgia Rheumatica
(diagnosis, drug therapy, physiopathology)
- Prednisone
(administration & dosage)
- Regression Analysis
- Remission Induction
- Severity of Illness Index
- Time Factors
- Treatment Outcome
|